Literature DB >> 23396977

Radiofrequency ablation of hepatocellular carcinoma extended into the portal vein: Preliminary results.

A Giorgio1, G de Stefano, A Di Sarno, N Farella, V Giorgio, U Scognamiglio, A Mariniello, G Liorre, A Perrotta, N Mariniello.   

Abstract

INTRODUCTION: We report our preliminary results of radiofrequency (RF) ablation of hepatocellular carcinoma (HCC) and neoplastic portal thrombus (NPT) in cirrhotic patients.
METHODS: Ten patients (7 males and 3 females; mean age 68 yrs) with 10 HCC nodules (37-49 mm) extended into the main portal vein (MPV) underwent RF ablation. Diagnosis of NPT was achieved by fine-needle biopsy. RF ablation was performed firstly on the NPT and then on the HCC. RF ablation was considered successful when complete necrosis of the HCC and complete recanalization of the MPV were achieved. HCC necrosis was evaluated using contrast-enhanced CT. Recanalization of the portal vessels (PV) was analyzed using Color Doppler (CD). RF ablation was performed under ultrasonographic (US) guidance using a perfused electrode needle.
RESULTS: Complete necrosis of the HCC with complete recanalization of the PV was observed in 7 patients (success rate: 70%). In the remaining 3, necrosis of the HCC ranged from 70% to 95%, and recanalization of the PV was not complete. No major complications occurred. In 2 cases, mild ascites and increased aspartate aminotransferase/alanine aminotransferase (AST/ALT) values were observed. The follow-up ranged from 4 to 24 months; 1 and 2-year survival rates were 77% and 77%, respectively. At the last follow-up, the 7 successful patients were alive and the portal system was still patent. The 3 unsuccessful patients died within 5 months due to progressive disease.
CONCLUSION: RF ablation can destroy HCC and NPT achieving a high rate of efficacy and low rate of complications. However, to confirm these results a control group and a longer follow-up are required.

Entities:  

Keywords:  Cirrhosis; Hepatocellular carcinoma; Portal vein; Tumor thrombus

Year:  2009        PMID: 23396977      PMCID: PMC3553089          DOI: 10.1016/j.jus.2008.12.004

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  21 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply.

Authors:  S Rossi; F Garbagnati; R Lencioni; H P Allgaier; A Marchianò; F Fornari; P Quaretti; G D Tolla; C Ambrosi; V Mazzaferro; H E Blum; C Bartolozzi
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

3.  Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins.

Authors:  Iwao Ikai; Yuzo Yamamoto; Naritaka Yamamoto; Hiroaki Terajima; Etsuro Hatano; Yasuyuki Shimahara; Yoshio Yamaoka
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

4.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

5.  Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance.

Authors:  Antonio Giorgio; Giovanna Ferraioli; Luciano Tarantino; Giorgio de Stefano; Vincenzo Scala; Ferdinando Scarano; Carmine Coppola; Luca Del Viscovo
Journal:  AJR Am J Roentgenol       Date:  2004-11       Impact factor: 3.959

6.  Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients.

Authors:  A Giorgio; L Tarantino; G de Stefano; A Perrotta; V Aloisio; L del Viscovo; A Alaia; G Lettieri
Journal:  Eur J Ultrasound       Date:  2000-12

7.  Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.

Authors:  E Villa; A Moles; I Ferretti; P Buttafoco; A Grottola; M Del Buono; M De Santis; F Manenti
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

8.  Surgical treatment of hepatocellular carcinoma with direct removal of the tumor thrombus in the main portal vein.

Authors:  M Konishi; M Ryu; T Kinoshita; K Inoue
Journal:  Hepatogastroenterology       Date:  2001 Sep-Oct

9.  Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography.

Authors:  Stefano Gaiani; Natascia Celli; Fabio Piscaglia; Laura Cecilioni; Franco Losinno; Francesco Giangregorio; Mikaela Mancini; Patrizia Pini; Fabio Fornari; Luigi Bolondi
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

10.  Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma.

Authors:  Antonio Giorgio; Luciano Tarantino; Giorgio de Stefano; Vincenzo Scala; Giulia Liorre; Ferdinando Scarano; Anna Perrotta; Nunzia Farella; Vincenza Aloisio; Nicola Mariniello; Carmine Coppola; Giampiero Francica; Giovanna Ferraioli
Journal:  AJR Am J Roentgenol       Date:  2003-08       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.